Verastem, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities MARKET INFORMATION Our common stock is publicly traded on The Nasdaq Global Market under the symbol “VSTM.” HOLDERS As of February 28, 2023 there were 7 holders of record of our common stock and the closing price of our common stock on The Nasdaq Global Market as of that date was $0.52. The number of holders of record does not include beneficial owners whose shares are held by nominees in street name. DIVIDENDS We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS The information required by this Item 5 of Form 10-K regarding equity compensation plans will be included in our 2023 Proxy Statement and is incorporated herein by reference. PERFORMANCE GRAPH The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, except to the extent that we specifically incorporate it by reference into such filing. The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq Biotechnology Index from December 31, 2017 through December 31, 2022. The comparison assumes $100 was invested after the market closed on December 31, 2017 in our common stock and in each of the foregoing indices, and it assumes reinvestment of dividends, if any. 67 Table of Contents Cumulative Total Return Comparison ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ ​ ​ 2017 2018 2019 2020 2021 2022 ​ ​ Verastem, Inc . 100.00 ​ 109.45 ​ 43.65 ​ 69.38 ​ 66.78 ​ 13.11 ​ ​ NASDAQ Composite 100.00 ​ 97.16 ​ 132.81 ​ 192.47 ​ 235.15 ​ 158.65 ​ ​ NASDAQ Biotechnology 100.00 ​ 91.14 ​ 114.03 ​ 144.15 ​ 144.18 ​ 129.59 ​ ​ ​ PURCHASE OF EQUITY SECURITIES We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K. Item 6. Reserved ​ ​ ​ 68 Table of Contents